The report summarizes data from more than 22 million cancer cases diagnosed at 1,250 ACS Commission on Cancer (CoC) hospitals from 2004 to 2022, the most recent years for which complete data is available. “As care at CoC-accredited facilities continues to advance, our hope is that this report reflects the vastly changing clinical landscape of cancer treatments using the latest evidence-based treatments.”Use of neoadjuvant systemic therapy increased notably for certain cancers. The researchers found that from 2010 to 2022, the use of neoadjuvant systemic therapy for gynecologic cancers rose nearly fivefold, from 7% to 34%. Substantial increases in neoadjuvant systemic therapy were also seen for pancreatic cancer, which more than tripled (12% to 40%), and for rarer cancers (peritoneum, omentum, and mesentery) that affect the abdominal lining and tissue, which nearly doubled (23% to 47%). “Historically, when we thought about treating solid tumors, the first expected treatment was to have surgery to remove the tumor.